Bromfenac ophthalmic solution (Bromday, ISTA Pharmaceuticals) 0.09% has been granted FDA approval as a once-daily prescription eyedrop for the treatment of postoperative inflammation and reduction of ocular pain in patients who have undergone cataract extraction.
Bromfenac ophthalmic solution (Bromday, ISTA Pharmaceuticals) 0.09% has been granted FDA approval as a once-daily prescription eyedrop for the treatment of postoperative inflammation and reduction of ocular pain in patients who have undergone cataract extraction.
ISTA expects to launch Bromday before the end of the year.
“We believe the convenience of a once-daily eyedrop will help with treatment compliance and benefit patients recovering from cataract surgery,” said Vicente Anido, Jr, PhD, president and CEO of ISTA, in a company press release.
“The recent approval of Bromday represents an important step in the evolution of ophthalmic drug delivery,” according to Robert Osher, MD, professor of ophthalmology, University of Cincinnati, and medical director emeritus, Cincinnati Eye Institute. “The fact that a potent NSAID can be effective with once daily usage will improve patient compliance while setting the pace for the rest of the industry.”
Examining Barriers to Care in Diabetic Retinopathy Screening
November 30th 2023Prior research has shown the association between various socioeconomic variables and lower adherence to diabetic retinopathy screening, but few have elaborated on the patient perspective to understand the reason behind this association.
A Three Pronged Approach to Driving Purchasing Compliance Across Your Pharmacy
November 29th 2023Navigate drug shortages successfully! This white paper unveils a 3-step strategy, empowering your pharmacy against the impact of 301 active shortages. Learn from industry leaders, optimize vendor relationships and ensure uninterrupted patient care. Download now for resilience in pharmacy purchasing challenges.